Alogliptin Benzoate CAS 850649-62-6 Raw Materials

CAS: 850649-62-6

MF: C25H27N5O4

Specification​: 99% min Alogliptin Benzoate Powder

Sample:  Alogliptin Benzoate Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Alogliptin Benzoate Powder Usage and Synthesis:

Alogliptin Benzoate is an oral medication used to treat type 2 diabetes. It belongs to the class of drugs known as biguanides, which lower blood sugar levels, promote insulin sensitivity and reduce hepatic glycogen synthesis. The main ingredients of this medication are alogliptin and benzoic acid, both of which are oral hypoglycemic agents.

Alogliptin benzoate is usually used as an oral medication once a day, 30 minutes before a meal is recommended. When using this drug, care should be taken to follow your doctor's advice and dosing instructions to avoid adverse reactions and drug interactions.

Pharmacokinetics of Alogliptin Benzoate Powder :

Glucagon is a peptide hormone produced by the gastrointestinal tract after a meal, which promotes insulin secretion from pancreatic β-cells, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), which are secreted by L-cells in the ileum and colon and K-cells in the duodenum, respectively. In patients with type 2 diabetes, enteroinsulin levels are significantly lower after meals, so preventing enteroinsulin inactivation to increase its duration of action would be effective in lowering blood glucose.

Alogliptin benzoate, as a DPP-4 inhibitor, decreases GLP-1 inactivation in the body by selectively inhibiting DPP-4 and increases GLP-1 levels in the body, thus lowering blood glucose. When blood glucose drops to normal levels, it does not continue to exert hypoglycemic effects, so it can effectively reduce the risk of hypoglycemia. In addition, DPP-4 inhibitors can delay gastric emptying, increase satiety, suppress appetite, and help patients reduce body mass.

Therefore, these drugs can reduce the risk of hypoglycemia and increased body mass while effectively lowering blood glucose, overcoming the barriers to patients' treatment attainment and bringing new hope to diabetes treatment.

Clinical Application of Alogliptin Benzoate Powder :

Alogliptin benzoate, also known as alogliptin, is a serine protease dipeptidyl peptidase IV (DPP-IV) inhibitor. It maintains the levels of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) in the body and promotes insulin secretion, thereby exerting a hypoglycemic effect.

The results of a randomized, placebo-controlled clinical trial showed that alogliptin monotherapy significantly improved glycemic control in patients with type 2 diabetes compared to placebo, did not increase the incidence of hypoglycemia, and was well tolerated.

Alogliptin and its drug combinations are effective oral specific DPP-IV inhibitors after sitagliptin and vildagliptin were introduced to the market, providing an important new therapeutic option for patients with type 2 diabetes with wide application prospects.